Liver cirrhosis

EA Tsochatzis, J Bosch, AK Burroughs - The Lancet, 2014 - thelancet.com
Cirrhosis is an increasing cause of morbidity and mortality in more developed countries,
being the 14th most common cause of death worldwide but fourth in central Europe …

Hepatorenal syndrome: pathophysiology, diagnosis, and management

DA Simonetto, P Gines, PS Kamath - bmj, 2020 - bmj.com
Hepatorenal syndrome (HRS), the extreme manifestation of renal impairment in patients with
cirrhosis, is characterized by reduction in renal blood flow and glomerular filtration rate …

Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association …

SW Biggins, P Angeli, G Garcia‐Tsao, P Ginès… - …, 2021 - Wiley Online Library
This AASLD Guidance provides a data-supported approach to the management of ascites
and HRS. It differs from the AASLD Guidelines, which are supported by systematic reviews …

Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study

E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong… - Gastroenterology, 2018 - Elsevier
Background & Aims Little is known about the natural course of nonalcoholic fatty liver
disease (NAFLD) with advanced fibrosis. We describe long-term outcomes and evaluate the …

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo …

C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan… - The lancet, 2019 - thelancet.com
Background Clinical decompensation of cirrhosis is associated with poor prognosis.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …

[HTML][HTML] Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013

R Jalan, J Fernandez, R Wiest, B Schnabl… - Journal of …, 2014 - Elsevier
Bacterial infections are very common and represent one of the most important reasons of
progression of liver failure, development of liver-related complications, and mortality in …

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri… - The Lancet, 2018 - thelancet.com
Background Evidence is scarce on the efficacy of long-term human albumin (HA)
administration in patients with decompensated cirrhosis. The human Albumin for the …

Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications

P Nahon, V Bourcier, R Layese, E Audureau, C Cagnot… - Gastroenterology, 2017 - Elsevier
Background & Aims We performed a prospective study to investigate the effects of a
sustained viral response (SVR) on outcomes of patients with hepatitis C virus (HCV) …

Coronavirus disease 2019 hangover: a rising tide of alcohol use disorder and alcohol‐associated liver disease

BL Da, GY Im, TD Schiano - Hepatology, 2020 - journals.lww.com
Abstract The coronavirus disease 2019 (COVID‐19) pandemic has had a tremendous global
impact since it began in November of 2019. However, there are concerns that the COVID‐19 …

[PDF][PDF] Management of adult patients with ascites due to cirrhosis: an update

BA Runyon - Hepatology, 2009 - Wiley Online Library
A Medline search from 1966 through 2007 was performed; search terms included ascites,
hepatorenal syndrome, diet therapy, drug therapy, radiotherapy, surgery, and therapy. The …